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Abstract
Hypoxia-inducible factor (HIF) α subunits are induced
under hypoxic conditions, when limited oxygen supply
prevents prolyl hydroxylation-dependent binding of
the ubiquitin ligase pVHL and subsequent proteasomal
degradation. A short normoxic half-life of HIF-α and a
very rapid hypoxic protein stabilization are crucial to
the cellular adaptation to changing oxygen supply.
However, the molecular requirements for the unusually
rapid mechanisms of protein synthesis, folding and
nuclear translocation are not well understood. We and
others previously found that the chaperone heat-
shock protein 90 (HSP90) can interact with HIF-1α in
vitro. Here we show that HSP90 also interacts with
HIF-2α and HIF-3α, suggesting a general
involvement of HSP90 in HIF-α stabilization. The PAS
B domain, common to all three α subunits, was
required for HSP90 interaction. ARNT competed with
HSP90 for binding to the PAS B domain since an
excess of either component inhibited the activity of
the other. HSP90 as well as the heterocomplex
members HSP70 and p23, but not HSP40, were
detected in immunoprecipitations of endogenous
cellular HIF-1α. While HSP90 and HSP70 bound to
HIF-1α predominantly under normoxic conditions,
ARNT bound to HIF-1α primarily under hypoxic
conditions, suggesting that ARNT displaced HSP90
from HIF-1α following nuclear translocation. Hypoxic
accumulation of HIF-1α was delayed in a novel cell
model deficient for HSP90β as well as after treatment
of wild-type cells with the HSP90 inhibitor
geldanamycin, suggesting that HSP90 activity is
involved in the rapid HIF-1α protein induction.
Introduction
The hypoxia inducible transcription factor-1 (HIF-
1) is an important regulator of the cellular response to
hypoxia [1, 2]. HIF-1 comprises two subunits, the oxygen
labile α-subunit and the constitutively expressed β-subunit
aryl hydrocarbon receptor nuclear translocator (ARNT)
[3]. HIF-1α is modified by oxygen-dependent prolyl
hydroxylation, allowing the binding of the von Hippel-
Lindau tumor suppressor protein (pVHL) that targets HIF-
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1α for ubiquitinylation and proteasomal destruction [4-
7]. Limited oxygen supply prevents hydroxylation and thus
degradation. This unusual mechanism of protein regulation
provides the basis for the extremely rapid HIF-1α
response to hypoxia which apparently occurs without any
measurable delay [8].
Activation of HIF-1α also involves nuclear
translocation, dimerization with ARNT, DNA-binding and
recruitment of transcriptional co-activators. These
processes can be triggered by post-translational
modifications of HIF-1α. It has been demonstrated that
activation of the PI3-kinase-PTEN-Akt-GSK3/FRAP and
the Ras/Raf-MEK-p42/44 kinase pathways eventually
result in elevated HIF-1α protein levels and/or
transcriptional activity of HIF-1 [9-11]. Under normoxic
conditions, HIF-1α is further modified by asparagine
hydroxylation, preventing the recruitment of transcriptional
co-activators [12-14]; and by lysine acetylation, promoting
pVHL binding [15]. Apart from HIF-1α, two other genes
encoding for the hypoxia-inducible factors HIF-2α/
EPAS1 and HIF-3α (including its splice variant IPAS),
respectively, have been reported [16-20]. All three α-
subunits share many similarities in terms of stabilization
and heterodimerization with ARNT.
Previous reports indicated that HIF-1α can bind to
the heat shock protein 90 (HSP90) in vitro [21, 22] or in
cells transfected with a fusion protein [23]. HSP90-
binding prevents degradation of many cellular proteins
including basic-helix-loop-helix (bHLH) transcription
factors such as the dioxin receptor and steroid hormone
receptors, p53 and protein kinases [24, 25]. In case of
the steroid hormone receptor, HSP90-binding also involves
HSP70, HSP40 as well as the co-chaperone p23 and
several immunophilins. The composition of this
heterocomplex is highly dynamic due to ATP-dependent
cycling. Upon exposure to heat, ATP-dependent
stabilization has been described for some of the HSP90
client proteins [24, 25].
In a prior study, we demonstrated that heat is also
sufficient to stabilize the unphosphorylated form of HIF-
1α under normoxic conditions, which was mediated by
HSP90-binding [26]. In addition, we and others found
that inhibition of HSP90 activity with geldanamycin,
novobiocin or radicicol prevents not only heat-induced
but also hypoxia-induced stabilization of HIF-1α [23, 26-
28]. Antibiotics of the ansamycin family such as
geldanamycin and novobiocin might thus be useful as small
molecule drug inhibitors of HIF-1α overexpression in
cancer cells [29-31]. Disruption of the HIF-1α-pVHL
interaction in pVHL-deficient cells or by prolyl
hydroxylation-defective HIF-1α mutants, did not affect
geldanamycin-induced proteasomal degradation of HIF-
1α [32]. These results suggest that Hsp90 protects HIF-
1α from oxygen-independent degradation by an
unidentified HIF-1α ubiquitin ligase.
Thus, HIF-1α might represent a novel HSP90 client
protein and HSP90 appears to regulate HIF-1α
stabilization. However, it can not be formally ruled out
that HSP90 antagonists inhibit HIF-1α stabilization by
unspecific mechanisms independent of HSP90 inhibition.
Therefore, we examined the hypoxic stabilization of HIF-
1α in a novel embryonic stem (ES) cell model established
from mouse blastocysts containing two targeted alleles
of the gene encoding HSP90β [33]. To further elucidate
the mechanism by which HSP90 regulates HIF-1α, we
investigated the protein-protein interaction with HSP90
in vitro and in vivo and we determined the HIF-1α
domain responsible for the interaction with HSP90.
Materials and Methods
Antibodies and Chemicals
Antibodies were purchased from the suppliers indicated
in parentheses: mouse monoclonal IgMκ anti-HSP90 (Affinity
Bioreagents), polyclonal rabbit anti-HSP90α (StressGen), mouse
monoclonal anti-HSP90 (StressGen), mouse anti-HIF-1α
(Novus), mouse anti-HSP70 (Alexis), rabbit anti-HSP40
(Calbiochem), mouse anti-p23 (Affinity Bioreagents), mouse
anti-β-actin (Sigma), control mouse IgG2 (Dako). Appropriate
horseradish peroxidase-labeled secondary antibodies were
purchased from SantaCruz and Promega. Geldanamycin was
purchased from Alexis. All other chemicals were obtained from
Sigma.
Plasmid constructions
The plasmid pBSKShuHSP90 was obtained from American
Type Culture Collection (ATCC) and contains the full-length
cDNA of human HSP90 which was subcloned into pcDNA3
(InvitroGen). Plasmids containing full length cDNAs for HIF-
1α, HIF-2α HIF-3α, ARNT and p23 were kindly provided by G.
L. Semenza (Baltimore, MD, USA), Y. Fujii-Kuriyama (Osaka,
Japan), C. A. Bradfield (Madison, WI, USA), L. Poellinger
(Stockholm, Sweden) and M. Garabedian (New York, NY, USA),
respectively. The PAS B domain of HIF-1α was deleted by
digestion with BspMI and AflII (MBI Fermentas), blunting with
Klenow polymerase and re-ligation, resulting in the loss of
amino acids 222 to 390 of HIF-1α [3].
Cell culture
Human HepG2 hepatoma cells were obtained from ATCC.
Cells were grown in high-glucose DMEM containing 10% FCS
(LifeTechnologies) in a humidified 5% CO2/95% air atmosphere
at 37°C. ES cells homozygous for an HSP90β null allele were
Katschinski/Le/Schindler/Thomas/Voss/WengerCell Physiol Biochem 2004;14:351-360
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isolated from blastocysts recovered from heterozygous HSP90β
intercrosses [33] as described previously [34]. ES cells were
cultured in high-glucose DMEM containing 20% FCS and 106
U LIF/l. Immortalized and transformed mouse embryonic
fibroblasts (MEFs) derived from wild-type and HIF-1α-deficient
mice were described previously [35]. For hypoxic exposure, the
O2 concentration in the cell culture incubator (InVivO2, Ruskinn,
Leeds, UK) was lowered to 1%.
Protein extraction and immunoblot analyses
Following stimulation, cells were collected, washed with
ice-cold PBS and extracted with 10 mM Tris-HCl (pH 8.0), 1 mM
EDTA, 400 mM NaCl, 0.1% NP-40, 1 mM DTT, 1 µg/ml aprotinin,
1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 mM PMSF. Protein
concentrations were determined using the Bradford method.
Proteins were separated by SDS-PAGE and transferred onto
nitrocellulose membranes by semi-dry electroblotting (Bio-Rad).
Membranes were stained with Ponceau S to verify equal protein
loading per lane. After overnight blocking (5% non-fat milk
powder in PBS), the blots were incubated with the primary and
secondary antibodies mentioned above. Chemiluminescence
detection was performed by incubating the membranes with
100 mM Tris-HCl (pH 8.5), 2.65 mM H2O2, 0.45 mM luminol and
0.625 mM coumaric acid for 1 min followed by exposure to X-
ray films.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed as described before [26].
Oligonucleotides containing a HIF-1 DNA-binding site derived
from the erythropoietin gene were gel-purified on 10%
polyacrylamide gels prior to 5' end-labeling of the sense strand
with γ32P-ATP (Amersham). Unincorporated nucleotides were
removed by gel filtration over Bio-Gel P60 columns (Bio-Rad).
Labelled sense strands were annealed to a twofold molar excess
of unlabelled antisense strands. DNA-protein binding reactions
were carried out for 4 hours at 4°C in a total volume of 20 µl 10
mM Tris-HCl (pH 7.5), 50 mM KCl, 50 mM NaCl, 1 mM MgCl2,
1 mM EDTA, 5 mM DTT, 5% glycerol, containing 5 µg nuclear
extract, 0.1 µg sonicated calf thymus DNA (Sigma), and 2 x 104
cpm of oligonucleotide probe. Samples were run on 4%
nondenaturing polyacrylamide gels at 200 V in TBE buffer (89
mM Tris, 89 mM boric acid, 5 mM EDTA) at 4°C. The gels were
dried and radioactive signals were recorded by
phosphoimaging.
Co-immunoprecipitation with in vitro translated
proteins
Coupled in vitro transcription and translation (IVTT) was
performed with rabbit reticulocyte or wheat germ lysates
according to the manufacturers recommendations (Promega).
HSP90 was translated in rabbit reticulocyte lysates and wheat
germ lysates were used for all other proteins. IVTTs (20 µl of
each reaction) were incubated for 2 hours at 4°C in a total
volume of 500 µl of MENG buffer (25 mM MOPS pH 7.5, 1 mM
EDTA, 0.02% NaN3, 10% glycerol, 20 mM sodium molybdate,
10 mM DTT). Subsequently, antibodies were added and
incubated for another 90 min. Finally, 100 µl of a 50%
proteinGplus/proteinA agarose slurry in MENG buffer
containing 5 mg/ml albumin were added for 90 minutes. Agarose
beads were washed three times with MENG buffer containing 2
mM sodium molybdate. Immunoprecipitated proteins were
recovered by adding 0.5 M Tris-HCl (pH 6.8), 0.5% SDS, 0.05%
bromophenol blue, 20% glycerol. Samples were cleared from
agarose beads by filtration through micropure 0.22 separators
(Amicon), boiled and separated by SDS-PAGE. The gels were
fixed in 50% methanol/10% acetic acid, dried and the radioactive
signals were recorded by phosphoimaging.
Co-immunoprecipitation with cellular protein extracts
Protein extracts (2 mg) were precleared with 100 µl
ProteinGplus/ProteinA agarose (Oncogene) in extraction buffer
containing 5 mg/ml bovine serum albumin. Subsequently, the
samples were incubated with anti HIF-1α (Novus) antibodies
for 2 hours. Protein Gplus/A agarose (100 µl) was added and
incubated overnight. The beads were washed, precipitated and
recovered as above. HIF-1α, HSP90, HSP70, HSP40 and p23
were detected by immunoblot analyses as described above.
Reporter gene assays
HepG2 cells were transiently co-transfected by
electroporation with expression vectors, a hypoxia-responsive
luciferase reporter gene (pH3SVL) and a constitutive renilla
expression vector (pRL-SV40) as described previously [36].
The expression vector pcDNA3 was either empty or contained
HSP90 or p23 full-length cDNAs (see above). The luciferase
reporter gene pH3SVL was driven by a SV40 promoter and
contained a total of 6 HIF-1 DNA-binding sites derived from
the transferrin gene [37]. Following transfection, the cells were
split and exposed to normoxic or hypoxic conditions. Reporter
gene activities were determined as described by the
manufacturer (Promega). Results were normalized to the values
obtained with the constitutive renilla reporter gene and are
expressed as hypoxia to normoxia ratios.
Results
All three HIF-α subunits interact with HSP90 in
vitro
To investigate the interaction between HIF-α
subunits and HSP90, co-immunoprecipitation assays of
in vitro translated proteins were performed. Radioactively
labeled HIF-1α (Fig. 1A) but not ARNT (Fig. 1B) co-
precipitated with HSP90. The specificity of this protein-
protein interaction was confirmed by the presence of
radioactively labeled HSP90 in HIF-1α precipitates (Fig.
1C). Similar results were obtained with radioactively
labeled HIF-2α and HIF-3α which co-precipitated with
HSP90 (Fig. 1D), suggesting that a domain common to
all three HIF-α subunits serves as the HSP90 interaction
interface.
Interaction of the HIF-1α PAS B domain with HSP90 Cell Physiol Biochem 2004;14:351-360
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 Fig. 1. Interaction of HIF
subunits with HSP90. In vitro
transcription/translation (IVTT)
followed by immuno-precipi-
tation (IP) of HSP90 (A, B, D) or
HIF-1α (C). Either HIF-1α (A),
ARNT (B), HSP90 (C), HIF-2α (D,
left) or HIF-3α (D, right) were
radioactively marked by incorpo-
ration of 35S-labeled amino acids
in IVTT reactions. The antibodies
used for immunoprecipitation
were derived against the non-
labeled interacting protein. IgMκ
(A, B, D) and IgG2b (C) isotype-
matched antibodies were used
for negative control immuno-
precipitations. Shown are phos-
phoimaging pictures of washed
co-immunoprecipitates separated
by SDS-PAGE.
Fig. 2. Inhibition of HIF-1α-HSP90 interaction by deletion of the HIF-1α PAS B domain or addition of ARNT. IVTT
followed by IP of HIF-1α (A) or HSP90 (B). Increasing amounts of ARNT, produced in a separate IVTT reaction, were
added to HSP90-HIF-1α interaction assays, followed by immunoprecipitation (IP) of HSP90 (C) or HIF-1α (D). Either
HSP90, wild-type HIF-1α, PAS B-deleted HIF-1α (∆PASB) or ARNT were radioactively marked by incorporation of
35S-labeled amino acids in IVTT reactions. IgMκ (C) and IgG2b (D) isotype-matched antibodies were used for negative
control immuno-precipitations. To equalize the total volume of lysate in the reaction, the indicated amounts of
unprimed reticulocyte lysate devoid of any plasmid were added. Note that some fragmentation of the labile HIF-1α
and ∆PASB proteins occured in these experiments, which, however, did not affect the general conclusions.
Katschinski/Le/Schindler/Thomas/Voss/WengerCell Physiol Biochem 2004;14:351-360
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Fig. 3. Inhibition of HIF-1-
dependent reporter gene
induction and DNA-binding
by HSP90. A Hypoxic
induction factors of a HIF-1-
dependent luciferase reporter
gene transiently transfected
into HepG2 cells. The pcDNA3
expression vector, containing
or not containing HSP90 and
p23 cDNAs, was co-
transfected together with the
firefly luciferase reporter gene
and a constitutive renilla
luciferase expression vector.
Shown are means ± s.d. of
relative values normalized to
the corresponding renilla
activities. *, p<0.05, n=3. B
EMSA of nuclear extracts derived from HepG2 kept for 4 hours at 20% or 1% O2. Supershift analysis with a monoclonal anti-HIF-
1α antibody confirmed the specificity of the HIF-1 bands. HSP90-primed or unprimed IVTT reactions were added to HIF-1 DNA-
binding reactions.
The PAS B domain is required for HSP90
interaction
The Per-ARNT-Sim (PAS) domain is an approx.
300 amino acids segment, which can be subdivided into
two copies of approx. 50 amino acids degenerate repeats
called the PAS A and PAS B domains. In the PAS family
of mammalian transcription factors, PAS domains
function as heterotypic and probably also homotypic
interaction interfaces. The PAS B domain of the dioxin
receptor is also a well-known HSP90 interaction domain.
We thus deleted the PAS B domain of HIF-1α, resulting
in ∆PAS B. Immunoprecipitation of radioactively labeled
∆PAS B demonstrated that antibody recognition was not
affected by the lack of the PAS B domain (Fig. 2A).
However, HSP90 was almost completely lost in the ∆PAS
B precipitates (Fig. 2A). This was further substantiated
by the presence of radioactively labeled HIF-1α but not
∆PAS B in HSP90 precipitates (Fig. 2B).
ARNT competes with HSP90 for HIF-1α binding
Because the PAS B domain of HIF-1α is also
involved in the interaction with ARNT, we determined
whether HSP90 and ARNT compete for binding to HIF-
1α. Therefore, increasing amounts of ARNT were added
to a HSP90-HIF-1α protein-protein interaction assay. As
shown in Fig. 2C, ARNT decreased the amount of
radioactively labeled HIF-1α in HSP90 precipitates,
suggesting that ARNT prevents HIF-1α-HSP90
interaction. Instead, increasing amounts of radioactively
labeled ARNT were found in HIF-1α precipitates (Fig.
2D), confirming that ARNT displaced HSP90 from the
HIF-1α binding site. Taken together, these data indicate
that binding of either ARNT or HSP90 to HIF-1α is
mutually exclusive.
HSP90 suppresses HIF-1 transactivation and
DNA-binding activity
To further investigate the model of HSP90-ARNT
competition for HIF-1α binding, we next determined the
impact of HSP90 dysregulation on HIF-1 function.
Therefore, HSP90 was overexpressed in HepG2 cells
by transient transfection and the influence of HSP90 on
endogenous HIF-1 transactivation activity was analyzed.
HIF-1 function was assessed by measuring the activity
of a co-transfected luciferase reporter gene under the
control of a total of six HIF-1 DNA-binding sites derived
from the transferrin gene [37]. Exposing transiently
transfected cells to hypoxia for 24 hours resulted in an
induction of about 20-fold when compared to normoxic
cells (Fig. 3A). Simultaneous transfection of a HSP90
expression vector, but not the empty expression vector
or a co-chaperone p23 expression vector, resulted in a
significant (p<0.05, n=3) decrease of the hypoxic reporter
gene induction (Fig. 3A).
To determine the influence of overtitrated HSP90
on HIF-1 DNA-binding, EMSAs were performed
Interaction of the HIF-1α PAS B domain with HSP90 Cell Physiol Biochem 2004;14:351-360
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employing an oligonucleotide that contains a conserved
HIF-1 DNA-binding site derived from the erythropoietin
gene. HIF-1 DNA-binding activity could be observed in
nuclear extracts derived from HepG2 cells cultured under
hypoxic but not normoxic conditions (Fig. 3B, left).
Supershift experiments using a monoclonal anti-HIF-1α
antibody confirmed the specificity of the HIF-1 signal.
Following the addition of IVTT HSP90, HIF-1 DNA-
binding activity decreased. Also the intensity of the
constitutive DNA-binding activity, which we previously
showed to consist of ATF/CREB family members [38],
decreased. However, the non-specific DNA-binding
activity was not affected by addition of HSP90 (Fig. 3B),
excluding a general suppressive effect on DNA-binding
in this assay. A slight suppression of HIF-1 DNA-binding
activity by unprimed IVTT extracts (Fig. 3B, right) could
be observed, which, however, did not account for the
strong suppression by HSP90 cDNA-containing IVTT
extracts.
Differential HIF-1α heterocomplex formation in
normoxic versus hypoxic cells in vivo
To investigate the interaction between HIF-1α and
HSP90 at the cellular level, HepG2 cells were exposed
to 1% oxygen for 4 hours. Cytoplasmic and nuclear
Fig. 4. Cellular inter-
action of HIF-1α with the
HSP90 heterocomplex. A
Immunoblot analysis of
HIF-1α and HSP90 in
nuclear extracts derived
from HepG2 cells kept for
4 hours at 1% O2. Cells
were lysed with NP-40 and
extracted with increasing
concentrations of NaCl as
indicated. B Immunoblot
analysis of HIF-1α
immunoprecipitates and
whole cell extracts of
normoxic and hypoxic
HepG2 cells extracted with
0.4 M NaCl. The same blot
was subsequently incu-
bated with the indicated
antibodies. HSP90 was
detected using a mono-
clonal anti-HSP90β anti-
body that detects pre-
ferentially but not exclu-
sively HSP90β (see Fig. 6).
Fig. 5. Hypoxic nuclear accumulation of HSP90
heterocomplex members in wild-type and HIF-1α-
deficient cells. MEF-HIF-1α+/+ and MEF-HIF-1α-/-
cells were kept for 4 hours at 1% O2. Cells were lysed
with NP-40, nuclei were extracted with 0.4 M NaCl,
and the extracts analyzed by immunoblotting.
protein was extracted in a NP-40 buffer containing
increasing concentrations of NaCl (0.2 - 1 M). As shown
in Fig. 4A, HSP90 co-immunoprecipitated together with
HIF-1α in HepG2 extracts, confirming the in vitro results.
Co-immunoprecipitations worked best in extracts prepared
with salt concentrations ranging from 200 to 400 mM
NaCl. Since HIF-1α was optimally extracted from the
nucleus by NaCl concentrations >200 mM [39] and
because 1 M NaCl hindered efficient immunoprecipitation
of HIF-1α (Fig. 4A), subsequent immunoprecipitations
were performed with 400 mM NaCl. Thus, this represents
a compromise between efficient HIF-1α extraction and
undisturbed immunoprecipitation.
Co-immunoprecipitations with total cellular extracts
derived from normoxic or hypoxic HepG2 cells revealed
that besides ARNT and HSP90 other members of the
HSP90 heterocomplex, such as HSP70 and probably p23,
co-immunoprecipitated with HIF-1α (Fig. 4B, left panel).
However, no HSP40 could be detected in this
heterocomplex, suggesting a specific composition. Of
note, slightly higher levels of HSP90 and HSP70 were
detected in HIF-1α precipitates derived from normoxic
cells than from hypoxic cells although the HIF-1α levels
were much lower in the normoxic cells. In striking contrast,
more ARNT could be found in the HIF-1α precipitates
Katschinski/Le/Schindler/Thomas/Voss/WengerCell Physiol Biochem 2004;14:351-360
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Fig. 6. Kinetics of HIF-1α expression in wild-
type and HSP90β-deficient ES cells. A
ES-HSP90+/+, ES-HSP90-/- and HepG2 cells were
exposed to 20% or 1% oxygen for 4 hours. Cell
extracts were analysed by immunoblotting,
employing a monoclonal anti-HSP90β antibody
that detects preferentially but not exclusively
HSP90β (top panel). The same blot was
subsequently incubated with a polyclonal anti-
HSP90α antibody (middle panel). To demonstrate
equal protein loading, a non-specific band is
shown (bottom panel). B ES-HSP90+/+ and ES-
HSP90-/- cells were kept for the indicated periods
at 1% O2. 1 µM geldanamycin was added where
indicated. HIF-1α protein levels were analyzed by
immunoblotting. Note that exposure times were
chosen which allowed to visualize both weak and
strong signals simultaneously, leading to an over-
exposure of the strongest signals.
derived from hypoxic cells than from normoxic cells. The
presence of detectable HIF-1α in normoxic cells can be
explained by the large amounts of protein extracts (2 mg)
used for the co-immunoprecipitations (Fig. 4B, left panel).
Indeed, straight immunoblot analysis with less protein
extracts (20 µg) allowed detection of HIF-1α in hypoxic
but not normoxic cells (Fig. 4B, right panel). These data
provide further evidence that the mutually exclusive HIF-
1α binding to HSP90 or ARNT found in vitro also takes
place at the cellular level in vivo, and they provide a first
link between oxygen concentration and HSP90
heterocomplex function in HIF-1 regulation.
Hypoxic nuclear accumulation of HSP90 is
independent of HIF-1α
Displacement of HSP90 from the HIF-1α PAS B
interaction site by ARNT is likely to occur in the nucleus
since ARNT is a constitutively nuclear protein [39].
However, under normoxic conditions HIF-1α most
probably is localized to the cytoplasm [40, 41] where it
interacts with HSP90 (see above). We previously
demonstrated by immunofluorescence analysis that
HSP90 accumulates in the nucleus following hypoxic
exposure of the cells without any change in total cellular
HSP90 concentrations [26]. One putative mechanism for
this finding could be nuclear co-translocation together with
HIF-1α. To test this hypothesis, MEFs wild-type or
deficient for HIF-1α were analyzed [35]. As shown by
immunoblotting, HSP90 but not the heterocomplex
members HSP70 and HSP40 accumulated in nuclear
extracts of hypoxically stimulated cells (Fig. 5, left part).
This effect was independent of the presence of HIF-1α
since in HIF-1α-deficient MEFs, HSP90 also
accumulated in the nucleus under hypoxic conditions (Fig.
5, right part). Of course, it cannot be excluded from these
experiments that HIF-2α or HIF-3α might be responsible
for HSP90 nuclear translocation. However, at least
regarding target gene induction the other HIF α subunits
are not capable of replacing HIF-1α function [35, 42].
HSP90 function is necessary for the rapid
hypoxic stabilization of HIF-1α
To elucidate the functional role of HSP90 in hypoxic
HIF-1α accumulation and activation, we established a
HSP90β-deficient cell model. Therefore, ES cells were
isolated from blastocysts recovered from intercrosses of
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heterozygous HSP90β-mutant mice. Western blot analysis
using a mouse monoclonal anti-HSP90 antibody, known
to react preferentially but not exclusively with HSP90β,
demonstrated a reduction in the HSP90 signal intensity in
HSP90β-deficient ES cells compared with wild-type ES
cells under normoxic and hypoxic conditions (Fig. 6A).
Subsequently, a rabbit polyclonal anti-HSP90α antibody
was applied. Also this antibody resulted in a reduction in
the HSP90 signal intensity in HSP90β-deficient ES cells
whereas a non-specific cross-reactive signal remained
unaffected, demonstrating equal loading between the
lanes (Fig. 6A).
Exposure of wild-type ES cells to hypoxia resulted
in a rapid and efficient accumulation of HIF-1α, reaching
maximal levels after 1 hour of hypoxic exposure (Fig.
6B, top panel). HIF-1α protein became detectable already
after 15 minutes of hypoxia (data not shown). In contrast,
in HSP90β-deficient ES cells the accumulation of HIF-
1α was delayed. Maximal HIF-1α levels were reached
only 4 to 6 hours after the onset of hypoxia (Fig. 6B,
middle panel). A delayed hypoxic response was also
observed in the wild-type ES cells treated with the HSP90
inhibitor geldanamycin (Fig. 6B, bottom panel), confirming
the results obtained with the HSP90β-deficient ES cells.
Therefore, HSP90 seems to play an important role in the
unusually rapid kinetics rather than in the on-off switch
of hypoxic HIF-1α protein stabilization.
Discussion
Previous studies indicated that HIF-1α interacts with
HSP90 under partially artificial conditions [21, 23]. We
confirmed and extended these results by demonstrating
that endogenous HIF-1α could be co-immunoprecipitated
together with the HSP90 heterocomplex from cultured
cells. The PAS B domain of HIF-1α was shown to be
required for interaction with HSP90. The PAS B domain,
and to a minor extend the bHLH domain, is also known
to be necessary for HSP90 interaction with the dioxin
receptor, another bHLH-PAS transcription factor [43-
45]. Interaction with HSP90 retains the inactive dioxin
receptor in a ligand-binding competent conformation in
the cytoplasm. Upon ligand binding, however, HSP90 is
displaced and the dioxin receptor translocates to the
nucleus where it interacts with ARNT. Since ligand-
binding and HSP90-interaction are two mutually exclusive
processes, HSP90 fullfills regulatory mechanism in dioxin
receptor signalling.
There is no ligand known capable of interacting with
the PAS domain of HIF-1α. However, hypoxia rather
than ligand-binding serves as the critical signal for HIF-
1α stabilization and activation. Indeed, we showed that
under hypoxic conditions, ARNT-binding to HIF-1α
increased whereas HSP90- and HSP70-binding
decreased. Adding excessive amounts of ARNT
competed with HSP90 for HIF-1α binding. Displacement
of HSP90 by ARNT from the PAS B domain seems to
be a critical step for full HIF-1 activation since addition
of HSP90 to the HIF-1 DNA-binding reaction or ectopic
overexpression of HSP90 inhibited DNA-binding and
transactivation activity. Consistent with our observations,
Erbel et al. resolved in a recent report the structural basis
for the interaction between the PAS B domains of HIF α
subunits and ARNT [46].
HSP90 inhibitors like geldanamycin and
novobiocin are able to promote proteasome-mediated
degradation of HIF-1α in an oxygen- and pVHL-
independent manner [23, 26, 27, 32]. Those agents are
naturally occurring ansamycin derivatives, exhibiting anti-
tumor activities [29-31, 47]. The HSP90 inhibitors are
interacting with the nucleotide-binding pocket of HSP90.
As a result, the binding of HSP90 to its client proteins is
counteracted, followed by the rapid degradation of those
instable proteins [48-50]. However, it can not be excluded
that these pharmacological HSP90 inhibitors are
degrading HIF-1α by indirect and/or unspecific
mechanisms. Therefore, we established a genetically
HSP90-deficient cell culture model. Vertebrates
ubiquitously express two cytosolic HSP90s (HSP90α and
HSP90β), the distinct biological functions of which are
not completely understood. Mutation of both HSP90 genes
is incompatible with cell growth in yeast. Knock-out mice
generated from HSP90β-deficient ES cells fail to develop
a fetal placental labyrinth and die at embryonic day 9.0/
9.5 despite full HSP90α activity [33]. Exposing the
HSP90β-deficient ES cells to hypoxic conditions in vitro
clearly demonstrated that full HSP90 activity is necessary
for the rapid hypoxic stabilization of HIF-1α. The presence
of both wild-type HSP90α alleles was not sufficient to
compensate for the lack of HSP90β function. A similar
effect could be provoked by treating wild-type ES cells
with geldanamycin, demonstrating that the activity of
geldanamycin likely is mediated by HSP90 inhibition.
In summary, a model is emerging in which the HSP90
heterocomplex is bound to the PAS B domain of HIFα
subunits and prevents the non-specific degradation of this
highly unstable protein by non-pVHL-mediated
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ubiquitination and proteasomal degradation. Under
normoxic conditions, HSP90 activity thus confers pVHL-
specific degradation of HIF-1α and inhibits HIF-1 activity.
Under hypoxic conditions, the lack of prolyl hydroxylation
prevents pVHL-mediated degradation of HIF-1α and the
HSP90 heterocomplex prevents unspecific degradation,
accelerating accumulation of HIF-1α. Disruption of
HSP90 function delays HIF-1α accumulation. Following
nuclear translocation, the high local concentrations of
ARNT displace HSP90 from the HIF-1α PAS B domain,
without the formation of a ternary complex, allowing the
heterodimerization essential for DNA-binding and gene
activation.
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